Rechercher des projets européens

15 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet

 26

 TERMINÉ 

Academia and Industry Collaboration for Digital Pathology (AIDPATH)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,

"Advances in digital pathology are generating huge volumes of whole slide and tissue microarray images which are providing new insights into the causes of some of today’s most devastating diseases. They also present tremendous opportunities for developing and evaluating new and more effective treatments that may revolutionize the care of patients with cancers and other diseases. The challenge is t ...
Voir le projet

 11

 TERMINÉ 

Recognising Adverse Drug Reactions (WEB-RADR)

Date du début: 1 sept. 2014, Date de fin: 31 août 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet

 20

 TERMINÉ 

Coordinating Action Systems Medicine – Implementation of Systems Medicine across Europe (CASYM)

Date du début: 1 nov. 2012, Date de fin: 30 avr. 2017,

The aim of CASyM is a combined large scale effort to sustainably implement Systems Medicine across Europe. For that purpose CASyM will function as a managing and coordinating platform in bringing together a critical mass of relevant European stakeholders such as Systems Biology scientists, clinicians, programme managers, industry/SMEs as well as healthcare providers and patient organizations. The ...
Voir le projet

 24

 TERMINÉ 

The development of in silico process models for roll compaction (IPROCOM)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

"Particulate materials, e.g. pharmaceutical formulations, precious metal, fine chemical, metal & ceramic powders, have been compacted to produce a wide range of particulate products in a number of industrial sectors. The diversity of particulate materials and the complexity of manufacturing processes make it a challenging task in product development and process design for particulate product manuf ...
Voir le projet

 10

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

Beta-cell function in juvenile diabetes and obesity (Beta-JUDO)

Date du début: 1 févr. 2012, Date de fin: 30 nov. 2016,

The number of individuals with obesity and type 2 diabetes mellitus (T2DM) is increasing. An alarming aspect is decline in age of onset of T2DM, which is coupled to rise in childhood obesity. Accentuated insulin secretion is observed early in young obese individuals. In many subjects insulin hypersecretion is evident when insulin sensitivity is essentially normal. Based on these observations we pr ...
Voir le projet

 12

 TERMINÉ 

Network for Integrated Cellular Homeostasis (NICHE)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

"There is a need for greater understanding of integrated cellular physiology to exploit cells and to tailor their activities to optimise microbial productivity in synthetic circuits and to limit microbial activity in food and pharmaceutical products. Understanding the integration of the cellular metabolic processes is fundamental to developing and exploiting cells. We have assembled a team of inte ...
Voir le projet

 9

 TERMINÉ 

Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,

RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of hi ...
Voir le projet

 42

 TERMINÉ 

The Body-on-a-Chip (BoC) (BOC)

Date du début: 1 juin 2012, Date de fin: 31 mai 2015,

High attrition and failures rates in pharmaceutical and biotechnological drug development require a paradigm change towards more physiological human cell-based assays at an early time point in the process. The central idea of this proposal is to develop a versatile and reconfigurable pharmaceutical screening technology platform that relies on organotypic three-dimensional spherical microtissues. T ...
Voir le projet

 5

 TERMINÉ 

The DNA damage response and breast cancer (DDRESPONSE)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2015,

We will exploit the DNA damage response (DDR) to assess and predict individual susceptibility and response focussed on breast cancer and breast cancer therapies. The 1st targeted therapy based on the DDR is inhibition of PARP by olaparib, which induces synthetic lethality in cancer cells with a specific DDR defect. Our members discovered olaparib, which is currently in Phase II trials. Its use in ...
Voir le projet

 6

 TERMINÉ 

The role of the Calcium Sensing Receptor (CaSR) in health and disease, implications for translational medicine (MULTIFACETED CASR)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,

The identification of the extracellular calcium sensing receptor (CaSR) was a crucial step in understanding nutrient sensing in mammals. In mammalian organisms the CaSR has multiple roles: besides calcium homeostasis, it is involved in protection against osteoporosis, blood vessel calcification, prevention against colorectal cancer, is involved in metastasis of breast and prostate cancer cells to ...
Voir le projet

 9

 TERMINÉ 

Innovative Synthesis in Continuous-Flow Processes for Sustainable Chemical Production (SYNFLOW)

Date du début: 1 sept. 2010, Date de fin: 31 août 2014,

The SYNFLOW vision is the paradigm shift from batch-wise large volume processes in pharmaceuticals, fine chemicals and intermediates production comprising many separate unit operations towards highly integrated but yet flexible catalytic continuous flow processing. For this purpose, SYNFLOW develops a unique integrative approach combining molecular understanding of synthesis and catalysis with eng ...
Voir le projet

 23

 TERMINÉ 

Translational Science for Vascular Inflammation and Remodelling (TranSVIR)

Date du début: 1 déc. 2009, Date de fin: 30 nov. 2013,

The rapid advance of biology is providing new insights into the causes of some of today’s most pressing medical problems as well as huge opportunities to develop and evaluate novel and more effective treatments. The challenge is to exploit these advances effectively and this will require a new breed of translational scientist with expertise in a specific discipline coupled with a broad understandi ...
Voir le projet

 6

 TERMINÉ 

Flexible, Fast and Future Production Processes (F³ FACTORY)

Date du début: 1 juin 2009, Date de fin: 31 juil. 2013,

The F3 consortium’s vision is that the EU’s chemical industry’s competitive position would be strongly enhanced if it could operate modular continuous plant (F3 plant) which combines world scale continuous plant efficiency, consistency and scalability with the versatility of batch operation. Our project will deliver such a radically new production mode based on: a) Plug–and–play modular chemical ...
Voir le projet

 29